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Background: Accurate, detailed, and standardized phenotypic
descriptions are essential to support diagnostic interpretation of
genetic variants and to discover new diseases. The Human
Phenotype Ontology (HPO), extensively used in rare disease
research, provides a rich collection of vocabulary with

standardized phenotypic descriptions in a hierarchical
structure. However, to date, the use of HPO has not yet been
widely implemented in the field of inborn errors of
immunity (IEIs), mainly due to a lack of comprehensive
IEI-related terms.
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Objectives: We sought to systematically review available terms
in HPO for the depiction of IEIs, to expand HPO, yielding more
comprehensive sets of terms, and to reannotate IEIs with HPO
terms to provide accurate, standardized phenotypic
descriptions.
Methods: We initiated a collaboration involving expert
clinicians, geneticists, researchers working on IEIs, and
bioinformaticians. Multiple branches of the HPO tree were
restructured and extended on the basis of expert review. Our
ontology-guided machine learning coupled with a 2-tier expert
review was applied to reannotate defined subgroups of IEIs.
Results: We revised and expanded 4 main branches of the HPO
tree. Here, we reannotated 73 diseases from 4 International
Union of Immunological Societies–defined IEI disease
subgroups with HPO terms. We achieved a 4.7-fold increase in
the number of phenotypic terms per disease. Given the new
HPO annotations, we demonstrated improved ability to
computationally match selected IEI cases to their known
diagnosis, and improved phenotype-driven disease classification.
Conclusions: Our targeted expansion and reannotation presents
enhanced precision of disease annotation, will enable superior
HPO-based IEI characterization, and hence benefit both IEI
diagnostic and research activities. (J Allergy Clin Immunol
2022;149:369-78.)
Key words: HPO, ontology, phenotype, rare diseases, inborn errors
of immunity, immunodeficiencies, disease classification, diagnostic
support, patient matching, genetic analysis

Rare and undiagnosed diseases pose challenges for affected
patients, clinicians, and researchers working to improve diagnostic and therapeutic approaches. Because of the rarity, clinicians often see only a few patients with specific rare phenotypes
throughout their careers, leading to considerable diagnostic
delay.1 Genetic research on rare diseases often relies on single
pedigrees or a few patients, leaving many patients undiagnosed.1
Compiling a cohort of patients—so-called patient matching—is
often crucial to gain insight into the phenotypic spectrum, natural/clinical history of the disease, and adequate monitoring and
treatment strategies. The rare disease community has recognized
these challenges and established tools enabling efficient data
sharing across institutions and borders, including genetic data exchange through the Matchmaker Exchange platform2 to solve undiagnosed exomes and genomes.3 These platforms, however, are
highly dependent on accurately phenotyped and categorized patients and standardized disease classifications.
To date, several nomenclatures and reference systems for
diseases have been developed.4,5 In parallel, ontologies were established to provide a more systematic, hierarchical classification
of diseases.6,7 However, these nomenclatures group patients by
disease label and do not describe the underlying phenotypic features. Consequently, clinical features, laboratory measurements,
and anatomical and functional phenotypes of patients are often
described with variable quality and specificity, which hampers patient matching, diagnostic efficiency, genetic variant prioritization in diagnostic pipelines, and global data exchange.
Given these challenges and the need for accurate, standardized
phenotyping, the Human Phenotype Ontology (HPO) system was
conceptualized and published with initial terminology in 2008.8,9
To date, HPO provides the most comprehensive deep phenotyping
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resource for rare diseases for clinicians, researchers, bioinformaticians, and electronic health record systems in the world.
HPO is used in many projects including the 100,000 Genomes
Project, the NIH Undiagnosed Disease Program and Network,
the Undiagnosed Diseases Network International, RDCONNECT, and SOLVE-RD.1,10-13 HPO is a community-based
tool and is increasingly adapted as the standard to describe phenotypic abnormalities for everyday use.14 Each term in HPO describes a distinct phenotypic feature (eg, lymphadenopathy,
HP:0002716), and the HPO tree structure allows similarity measures between patient phenotypes. HPO contains more than
200,000 phenotypic annotations for hereditary diseases, of which
2,120 are considered rare diseases. Inborn errors of immunity
(IEIs) form a subgroup of these rare diseases. Clinical experts
in IEI agree that a major barrier to the adoption of HPO terminology is that it has not been used widely for IEIs. This is partly due
to the lack of disease-specific HPO terms to describe patients with
IEI.15 Adequate depiction of the complex clinical and immunologic phenotypes of IEI disease entities with HPO terms would
allow discrimination between heterogeneous groups of IEIs.
Illustrating the lack of terms, in 2017, HPO contained more
than 11,000 terms, of which 5,000 terms have been applied to
the musculoskeletal system, with only 1,000 terms related to
IEIs.9,15 In addition, the phenotypic annotation of IEIs often includes results of specific immunologic assays, which pose a challenge to accurately reflect in HPO terms.15 Because of the lack of
specific HPO terms depicting results of laboratory assays, often a
nonspecific broader term is used for the annotation of IEIs. Therefore, HPOs are currently not specific enough to be used for genetic
analysis and diagnostic aid for IEIs. In a study addressing the clinical efficacy of genetic testing in IEI, bioinformatics tools using
existing HPO terms missed the disease-causing gene in 37% of
the patients with known monogenic disorders.16 In this study,
we set out to improve HPO terminology for IEIs by applying established bioinformatic methodologies coupled with expert review. The aims of this project were therefore to (1)
systematically review existing HPO terms for IEIs, (2) revise
ontology structures, (3) add missing terms, as well as (4) reannotate existing IEIs with HPO terms, to collectively enable systematic use of HPO by the IEI community.

METHODS
Spearheaded by the European Reference Network on Rare Primary
Immunodeficiency, Autoinflammatory and Autoimmune diseases (ERNRITA) and the European Society for Immunodeficiencies (ESID), we set up
working groups comprising members of the participating immunodeficiency
societies to revise and expand HPO terms for IEIs. Three workshops,
numerous teleconferences, and joint task forces took place over the span of
2 years, with more than 30 participants including expert clinicians, geneticists,
researchers working on IEIs, and bioinformaticians. All participating
clinicians and geneticists identified through the ERN-RITA, ESID, and the

HAIMEL ET AL 371

J ALLERGY CLIN IMMUNOL
VOLUME 149, NUMBER 1

IUIS
Table 1
Immunodeficiencies
affecting cellular
and humoral immunity

IUIS
Table 3

IUIS
Table 4

Predominantly
antibody deficiencies

Diseases of
immune dysregulation

IUIS
Table 7

Autoinflammatory
disorders

1. Collection of
reviews/case
reports

Extraction of HPO terms with text miner
Preparation of summaries per disease

2. Text mining,
data processing

3. Two-tier
expert review

Evaluation
by experts

4. Data processing,
submission

Evaluation
by experts

Evaluation
by experts

Evaluation
by experts

Data filtering and summary
Main coordinators

Updates to HPO

FIG 1. Pipeline for standardized reannotation of IEI diseases. First, scientific publications were collected by
experts for each disease within the subgroups. Second, HPO terms were extracted from the provided
publications for each disease using machine learning and summarized into Excel documents. Third, a 2-tier
expert review evaluated the text-mined terms, suggested additional terms if required, and the responsible
working group agreed on the final HPO annotations for each disease. Fourth, data were collated, and the
agreed terms were submitted to HPO.

International Society of Systemic Autoinflammatory Diseases are established
experts in their fields from different European countries and North America.
Additional scientific support provided the indispensable bioinformatics
expertise.

submitted HPO terms is detailed in the Document S1 in this article’s Online
Repository at www.jacionline.org. In addition, missing terms describing pulmonary and gastrointestinal complications of primary antibody deficiency
(PAD) were discussed during teleconferences and thereafter submitted to update the HPO ontology. A list of HPO resources can be found in this article’s
Methods section in the Online Repository.

Establishment of working structure
A remote working structure (detailed in this article’s Methods section in the
Online Repository at www.jacionline.org) was launched to address gaps in the
HPO tree and in the annotation of IEI diseases.

Expansion and restructuring of disease-related
branches of the HPO tree
Disease-specific HPO restructuring was discussed within 4 working
groups. Each group focused on a different HPO branch; the suggested changes
were agreed on among all participants. Differences between centers and
countries in the use of terms and definitions were highlighted during the faceto-face workshops. The results were summarized electronically in Excel
documents or pictures and flipchart drawings by the main coordinators before
being submitted to HPO. The full list of restructured tree elements and new

Standardized reannotation of rare, genetically
diagnosed diseases
A 4-step process was developed for a standardized reannotation effort
across working groups and to consistently annotate IEIs (spanning more than
300 different diseases in Online Mendelian Inheritance in Man) with HPO
terms (see Fig 1). Because IEIs represent a large and heterogeneous group of
rare diseases, we here decided to selectively focus on defined subgroups of IEI
to test the feasibility and usefulness of such an endeavor. First, publications
were collected by experts for each disease within the subgroups (minimum
of 2 articles per disease), representing key phenotypic presentation(s) of the
specific disease. In the second step, HPO terms were extracted from the provided publications for each disease using machine learning17 (explained in
detail in this article’s Methods section in the Online Repository) and
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FIG 2. Revision and expansion of the HPO tree. A, Schematic representation of the restructuring of the HPO
tree. Main branches of the HPO tree where restructuring was performed are marked with light green. B, ‘‘Abnormality of temperature,’’ ‘‘Abnormality of immunoglobulin level,’’ and ‘‘Unusual infections’’ as examples
of revised branches of the HPO tree. New additions and suggestions are marked with green, and repositioned terms are marked with yellow.

summarized into Excel documents. Third, a 2-tier expert review evaluated the
text-mined terms, suggested additional terms if required, and the responsible
working group agreed (defined as at least 80% agreement among group experts) on the final HPO annotations for each disease. Fourth, the validated
terms were submitted to HPO. Document S2 in this article’s Methods section
in the Online Repository contains the reannotated diseases, and the list of reannotated terms for each disease is available in Document S3 in this article’s
Methods section in the Online Repository.

Standardized reannotation of genetically
undiagnosed diseases
The methods above were specifically designed for application in (very) rare
diseases, where the number of patients and therefore the described phenotypic
spectrum and clinical presentation is sparse. In case of diseases and disease
groups where an adequate amount of patient and phenotype data were
available, in addition to a True/False annotation, the frequency of each
phenotypic item was assessed. The frequencies correspond to the following
representation in patients: common 5 Frequent (79%-30%); sometimes 5
Occasional (29%-5%); rare 5 Very rare (<4%-1%).

RESULTS
Systematic evaluation and expansion of the HPO
structure and terms relevant to IEIs
Our approach has resulted in the restructuring of 4 main
branches of the HPO tree, namely (1) abnormality of the immune
system (HP:0002715), (2) abnormality of metabolism/homeostasis (HP:0001939), (3) abnormality of the integument
(HP:0001574), and (4) abnormality of the cardiovascular system
(see Fig 2, A, and Document S1 in this article’s Online Repository
at www.jacionline.org). Together, this revision prompted the
replacement/restructuring of 67 terms, and the addition of 57
new terms to the HPO tree, among them ‘‘recurrent fever,’’ ‘‘unusual infections,’’ ‘‘IgG levels in blood’’ (see Fig 2, B, and
comprehensive list in Documents S1 and S2 in this article’s Online Repository at www.jacionline.org).

HPO information content measures, and disease
patient similarity measures

Directed expansion of PAD terms
Overall, the PAD working group focused on replacing broad and
nonspecific terms with terms that describe phenotypes in more
detail and accuracy (eg, ‘‘partially absent total IgG/IgA/IgM in
blood’’ and ‘‘(near) absent total IgG/IgA/IgM in blood’’ instead
of ‘‘hypogammaglobulinemia’’) (Fig 2, B). In addition, we proposed that the full detailed spectrum of specific antibody as well
as IgG-subclass deficiencies be described by separate HPO terms.
For example, we described individual terms related to ‘‘decreased
specific antibody response to vaccination in blood’’ divided according to the response to different types of vaccination (protein,
protein-conjugated
polysaccharide,
and
unconjugated
polysaccharide).

Information content of all HPO terms was assessed with the R package ontologyIndex v2.5.18 The phenotypic similarity of diseases and patients before
and after reannotation was compared using the R package ontologySimilarity
v2.3.18 The Euclidean distances between the diseases were computed on the
basis of similarity measures, clustered with hierarchical clustering and visualized with ggtree using the R packages ggtree19 and ape v5.2.20
A detailed description including the data processing pipeline and tools is
available in this article’s Methods section in the Online Repository.

Standardized reannotation of rare, genetically
diagnosed IEIs
We started by a systematic review of 4 disease categories of the
International Union of Immunological Societies (IUIS) classification of IEIs, as proof of concept: diseases affecting cellular and

Patient cohort
We randomly selected 30 patients who harbored a genetic diagnosis in one
of the reannotated diseases from a large pediatric referral center research
database. Clinical summaries of these patients before genetic diagnosis were
retrieved by an expert clinician. The clinical summaries were parsed and HPO
terms were extracted using machine learning as described in this article’s
Methods section in the Online Repository.
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FIG 3. Results of disease reannotation. A, HPO annotation availability in the subset of 72 diseases. B, Distribution of number of available HPO terms per disease. C, Pipeline for the reannotation process. D, Distribution of the number of articles used per disease for the reannotation pipeline. E, Number of mined terms
per disease. Each dot represents a disease. F, All mined vs all accepted terms. G, Number of available terms
per disease before and after reannotation. Each dot represents a disease. H, Mean information content available per disease before and after reannotation. I, The aggregate mean annotation per disease after reannotation. J, All text-mined terms from PAD publications. K, Frequency distribution of different PAD terms
according to the experts.

humoral immunity (IUIS Table 1), diseases of immune dysregulation (IUIS Table 4), autoinflammatory disorders (IUIS Table 7),
and genetically undiagnosed predominantly antibody deficiencies
(IUIS Table 3), detailed in Table E1 and Document S3 in this article’s Online Repository at www.jacionline.org. As a first step,
we assessed the already available HPO annotation for each disease in the v2019-06-03 HPO release (see this article’s Methods
section in the Online Repository). We found that 15% of diseases
considered (11 of 73 diseases in total) did not have any associated
HPO terms (Fig 3, A). Overall, we found that on average 13.3
phenotype terms were available per disease (Fig 3, B), later
referred to as ‘‘existing terms.’’
The text-mining and evaluation process was separated into 4
steps shown in Fig 3, C. We have first focused on the reannotation
of 72 genetically diagnosed IEIs, and genetically undiagnosed
PADs. For genetically diagnosed IEIs, text mining was based
on 162 expert-curated articles, on average 2.57 articles per disease (Fig 3, D). This resulted in 4,517 extracted phenotype terms,
66.42 terms per disease (Fig 3, E). Of these terms, 3,242—or 71%
per disease (47.67 of 66.42)—were accepted as correctly attributed terms by the expert reviewers (Fig 3, F). Expert suggestions

added up to 529 additional HPO terms, in addition to the existing
and text-mined terms.
After reannotation, a mean of 63.1 terms were available for
each disease, resulting in a 4.7-fold gain in the number of
available annotations (Fig 3, G). The mean information content as
measured by the overall frequency of terms in each disease’s annotations has increased from 6.17 to 8.3 (Fig 3, H) after
reannotation.
The new annotation of diseases consisted mainly of text-mined
terms (70.6%) (Fig 3, I), followed by already existing terms
(9.3%) and additional suggestions by experts (9.3%; adding a
further 5.2 additional terms per disease) (see Document S3 in
this article’s Online Repository).

Standardized reannotation of genetically
undiagnosed PADs
PADs form a heterogeneous group, and most PADs do not (as
yet) have a genetic diagnosis. We collected articles describing the
heterogeneous PADs related to common variable immunodeficiency disorders, agammaglobulinemia, selective IgM deficiency,
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fever episodes (HP:0001945 ) that lasted
longer than ten weeks (HP:0001954 ),
accompanied by episodes of rigor (HP:
0025145) and returning rash (HP:
0000988). In addition, the boy regularly
experienced abdominal pain (HP:
0002027).

Density
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FIG 4. Patient-disease matching. A, Schematic overview of the different steps of patient-to-disease matching. First, the phenotypes were identified in a patient’s clinical history. Second, these phenotypes were
translated to HPO terms. Finally, patient phenotype to disease matching was measured by Lin similarity.
B, Matching patient 1 to a diagnosis. C, Similarity of patients in patient cohort to genetic diagnosis before
and after reannotation. D, The rank of correct clinical diagnosis more often is in the top 10 of matched diseases after reannotation. E, Improvement of ranks of clinical diagnosis before and after reannotation. Significance was assessed by Student t test.

selective IgA deficiency, IgG-subclass deficiency, specific antibody deficiency, and unclassified antibody deficiency subgroups.
In total, 541 terms were text mined from these articles, many of
these in more than 1 PAD subgroup, and 245 of these terms
(45.2%) were annotated as correctly associated to the respective
PAD subgroup by the expert reviewers (Fig 3, J). Of these 245
terms, the experts annotated 16.3% as commonly found in
PADs, 48.97% as sometimes associated (albeit less commonly),
and 34.7% as rarely associated with PAD (Fig 3, K).

Patient-disease matching
We set out to showcase the efficacy of our reannotation effort
by highlighting the potential diagnostic impact of optimized
disease annotation. To do this, we have selected 30 clinical cases
from a large immunology referral center research database (see

Online Repository Document S3). HPO terms were matched to
patient phenotypes by experts from the clinical synopsis, and
the phenotypic similarity to all HPO-annotated diseases was
calculated on the basis of these selected patient HPO terms (Fig
4, A), as illustrated by a concrete clinical example of a patient
with tumor necrosis factor receptor–associated periodic syndrome (Fig 4, B). Overall, we show a significant improvement
by 47% in the specificity of patient phenotype matching to correct
diagnosis (from 0.49 to 0.72; P 5 1.8 3 10207; Fig 4, C), and a
significantly better ranking of the correct clinical diagnosis across
all possible diseases after reannotation: in most cases, the correct
diagnosis was in the top 10 of matched diseases (Fig 4, D) after
reannotation, and the rank of the correct diagnosis for individual
patients was highly significantly improved, from a mean of 285 to
19 (14.9-fold improvement; P 5 9.1 3 10207; Fig 4, E).
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Phenotype-driven disease classification
We tested the efficacy of our approach in selecting biologically
and clinically meaningful phenotypes by assessing the HPObased phenotypic similarity of diseases before and after reannotation. In particular, we assessed whether the similarity was
greater within or between IUIS clinically defined groups. We
found that the phenotype-driven disease classification after
reannotation has resulted in a clustering more in concordance
with the IUIS-based clinical classification (see Fig 5, A and B).
DISCUSSION
Unified data standards, consistent classification, and robustly
verified clinical data are vital pillars supporting diagnostic
pipelines and data-driven research. Although databases and
vocabularies that aim to provide accurate phenotypic descriptions
exist,5-9 there are still major gaps in the depiction of IEIs in these
data sets. Here, we used a cross-community collaboration to review, expand, and improve the depiction of IEIs in HPO, and reannotate IEIs with HPO terms. We reviewed 4 separate branches
of the HPO tree and submitted 57 new and expanded HPO terms,
most of which are now included in the official HPO data set. We
introduced a semi-automated reannotation pipeline, which combines ontology-guided machine learning and a 2-tier expert review to reannotate 4 main categories of IEIs. The basis of the
ontology-guided machine learning was the expert-curated list of
articles (162 in total), which was submitted to the PanelApp21
to serve as a public resource. The text-mined phenotypes were
subjected to expert review to confer face validity or refute the putative new HPO terms. IEIs and their current HPO terms covered
by the working groups were scrutinized in-depth, resulting in
high-quality annotations. Overall, we have achieved a 4.7-fold
gain in the number of HPO terms annotating each disease. These
annotations included unspecific (frequently annotated) as well as
specific (less frequently annotated) HPO terms holding less and
more information content, respectively. Combined, the mean information content increased from 6.17 to 8.3.
Each reannotated disease showed an increase in information
content and a quantitative gain in the number of available HPO
terms. Through patient-disease matching and disease-similarity
examples, we illustrated that these gains and increases translated
to significant qualitative improvement in patient-disease matching in an independent cohort of patients with IEI (Fig 4), and
phenotype-driven classification of IEIs that more closely resembles clinical consensus (Fig 5). Although neither of these measures are systematic assessments of global patient-disease
matching and disease-similarity comparisons, they highlight
that there is considerable benefit by the revision of specific subclasses of diseases. Once a near-complete HPO phenotype reannotation of almost all IEIs is available, it will be intriguing to
assess how well patients with genetic diagnoses match reannotated Online Mendelian Inheritance in Man (OMIM) diseases in
a clinical setting, how patient matching to genetic diagnosis is
transformed, and whether these changes ultimately lead to an
earlier diagnosis. Finally, once a detailed and accurate phenotypic
description is available for all IEIs, identification phenotypedriven patient subgroups will be common practice, and a more
objective entirely phenotype-driven classification and ontology
of IEIs can become a reality.
Accurate phenotypic description of patients holds promise for
diagnostic utility and for the discovery of novel diseases.

HAIMEL ET AL 375

Phenotype-driven genetic diagnostic tools now exist, but their
full clinical potential is hampered by the lack of complete
phenotypic descriptions for most types of IEIs. Phenotips22 is a
free and open source software for collecting and analyzing phenotypic information of patients with genetic disorders that is widely
used in the rare disease community. Tools such as Exomiser use
HPO terms to annotate and to prioritize potentially casual variants.23 New integrative ‘‘omics’’ approaches and the analysis of
large-scale data with artificial intelligence will allow us to go
from a one-size-fits-all to a more personalized medicine,
including in IEIs. We see the potential to integrate the richer phenotyping of previously undiagnosed groups of patients with IEI
with available sequencing data to accelerate disease gene discovery and at the same time increase the diagnostic rate in new
patients.24
Novel disease-gene or phenotype associations depend on
sufficient numbers of cases as well as a control cohort of
comparable quality. Cross-institute and cross-country collaborations for cohorts of undiagnosed, but well-phenotyped patients
could shed light on novel disease-causing genes of the immune
system. Trusted and accepted data and information sharing
platforms are already being developed13,22 to provide robust
and sufficiently granular HPO terms as a standardized way of phenotyping patients. Electronic health records25 could facilitate the
transfer of HPO terms by integrating with available sharing platforms. Capturing HPO annotations of novel rare diseases or cases
is an ongoing challenge for a complete disease representation.
Thus, it is important that alongside of updating the official IUIS
classification, HPO descriptions of disorders are curated once
every several years. We suggest a community effort for such regular reviews of HPO regarding IEIs, such as a team of experts, part
of big international groups of clinicians such as ESID or ERNRITA, the Clinical Immunology Society (CIS), or other similar
organizations. Publication standards that require the submission
of HPO annotations upfront would greatly improve this process.
Once phenotyped patients are available, robust and global
approaches are accessible2 to find phenotypically similar cases.
These comparisons are performed by advanced machine learning
algorithms. However, machine learning can also be a very
powerful tool to automate the identification of relevant phenotype
information in publications or clinical notes. We applied an
ontology-guided machine learning tool to support the annotation
of diseases and explored the full spectrum of terms—from very
relevant to not relevant at all. The same process can be applied
to unstructured clinical notes to accelerate in-depth annotation
of patients. For patients with electronic health records,25
abnormal clinical values can automatically be translated into
HPO codes26 for a more precise diagnostic application and
integrated with sharing platforms as mentioned before. The foundation of these comparisons is an ontology with a comprehensive
set of terms, which is widely used.
Because there is currently no criterion standard on how to
perform an expert-based review of ontologies, guidance on
annotating diseases with HPO phenotypes can vary between
diseases, disease classes, and centers. IEIs are rare diseases, and
often there are only a few patients described (sometimes only 1
kindred in case of ultra-rare diseases). Therefore, the depth of
currently available published phenotypes is at times limited. The
low number of patients and insufficient depth of available
phenotypes bring up a question as to which diseases to include
in phenotyping exercises of this nature. On the one hand, focusing
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FIG 5. Phenotypic similarity of diseases before and after reannotation. Diseases are annotated with the IUIS
disease group (inner circle), subgroup (outer circle), and OMIM identifier. A, Clustering of diseases based on
phenotypic similarity before reannotation. B, Clustering of diseases based on phenotypic similarity after reannotation. OMIM, Online Mendelian Inheritance in Men; SCID, severe combined immunodeficiency.
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on IEIs that are commonly accepted, with multiple patients
diagnosed and well described by multiple researchers, can
increase the depth of phenotyping. However, this approach
excludes at least 10% of IEIs (the ultra-rare diseases). On the
other hand, an all-inclusive approach including every disease
systematically means that we rely on sparsely phenotyped
patients and perhaps insufficient data for ultrarare disorders.
A warning of accuracy by indicating the frequency of each
phenotype for diseases could soon be possible, with the addition
of phenotype frequency to the HPO data set, an expansion that is
currently work in progress. This implies the need for a responsive
system, capable of assimilating new phenotypic information as
the pool of confidently diagnosed patients increases.
Our ongoing approach aims to address these gaps for IEIs and
to provide an ontology that is practical, useful, and as complete as
possible. However, the existence of a well-built ontology and the
awareness of clinicians and researchers itself does not guarantee a
shift in the community to fully adapt a standardized phenotyping
approach. Our approach raised awareness regarding the concept
and importance of HPO among the IEI community. Moreover, the
process made the participating clinicians aware of the available
terms and highlighted where these were lacking. Moving forward,
it is very important that official entities adopt HPO terms as the
unified means of patient phenotyping. We hypothesize that as
soon as the widely used registries such as the Undiagnosed
Disease Network11 or the IUIS27 use HPO to refer to phenotypic
annotation, this will propel the IEI field toward adopting HPO as
the main nomenclature for phenotyping patients with IEI. One
promising move in this direction is the recent expansion of the
ESID registry working definitions for the clinical diagnosis of
IEIs,28 which derives HPO terms from OrphaNet using the
ORDO Ontological Module (HOOM) platform,29 prompted by
our HPO initiative.

Conclusions
Our work reviewed and expanded the phenotypic depiction of
multiple subclasses of IEIs, and to our knowledge, this initiative is
the first endeavor of its kind with the aim of standardizing IEI
phenotypes. Our semiautomated annotation-based approach is
scalable to include all IEIs as illustrated herein. We propose our
reannotation approach as a blueprint for systematic HPO (re)
annotation for additional immunologic and nonimmunologic
diseases.
Key messages
d

HPO is a robust resource for supporting IEI diagnostics
and genetics with adequate ontology breadth and disease
annotation depth.

d

Following systematic reannotation of IEIs, the HPObased phenotype-driven classification improved and now
closely resembles clinical consensus.

d

Significant increase in matching patients to the correct diagnoses is achieved by systematic reannotation of IEIs.
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